{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:31:47Z","timestamp":1777923107240,"version":"3.51.4"},"reference-count":44,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"\n Infectious complications caused by multidrug-resistant bacteria are a serious clinical and therapeutic problem. Our study aimed to analyze the genetic characteristics of extended-spectrum \u03b2-lactamase-producing\n Enterobacterales<\/jats:italic>\n (ESBL-E) that cause multidrug-resistant infections in patients with solid tumors. Identification of ESBL-encoding genes was performed by polymerase chain reaction (PCR) and sequencing. The clonal relationship of the isolates was evaluated by pulsed-field gel electrophoresis. Multilocus sequence typing (MLST) was carried out for selected\n Escherichia coli<\/jats:italic>\n and\n Klebsiella pneumoniae<\/jats:italic>\n isolates. All\n E. coli<\/jats:italic>\n strains were classified into phylogenetic groups using the PCR-based approach. There were 735 patients with clinical symptoms of infections tested, of which 44 (6.0%) were positive for ESBL-E on genotypic testing. The most frequent organism was\n E. coli<\/jats:italic>\n (\n n<\/jats:italic>\n \u2009=\u200924, 54.5%), followed by\n K. pneumoniae<\/jats:italic>\n (\n n<\/jats:italic>\n \u2009=\u200913, 29.5%),\n Proteus mirabilis<\/jats:italic>\n (\n n<\/jats:italic>\n \u2009=\u20093, 6.8%),\n Enterobacter cloacae<\/jats:italic>\n cplx (\n n<\/jats:italic>\n \u2009=\u20092, 4.5%), and\n Klebsiella oxytoca<\/jats:italic>\n (\n n<\/jats:italic>\n \u2009=\u20092, 4.5%). Overall, 31 (70.5%) of the ESBL-E isolates carried only\n bla<\/jats:italic>\n CTX-M-1<\/jats:sub>\n -like genes, and the genes were found to be\n bla<\/jats:italic>\n CTX-M-15<\/jats:sub>\n (\n n<\/jats:italic>\n \u2009=\u200930, 68.2%) or\n bla<\/jats:italic>\n CTX-M-3<\/jats:sub>\n (\n n<\/jats:italic>\n \u2009=\u20091, 2.3%). Eleven strains (25%) had\n bla<\/jats:italic>\n CTX-M-9<\/jats:sub>\n -like genes, mostly\n bla<\/jats:italic>\n CTX-M-27<\/jats:sub>\n (\n n<\/jats:italic>\n \u2009=\u200910, 22.7%) and unique\n bla<\/jats:italic>\n CTX-M-65<\/jats:sub>\n (\n n<\/jats:italic>\n \u2009=\u20091, 2.3%). One isolate possessed both\n bla<\/jats:italic>\n CTX-M-15<\/jats:sub>\n and\n bla<\/jats:italic>\n CTX-M-27<\/jats:sub>\n genes, and another one produced TEM-12 ESBL. MLST analysis revealed\n E. coli<\/jats:italic>\n sequence type (ST) 131 and ST361, and\n K. pneumoniae<\/jats:italic>\n ST16, ST307, and ST437. Among\n E. coli<\/jats:italic>\n isolates, the B2 phylogenetic group was predominant. Most of the strains showed resistance to third-generation cephalosporins and fluoroquinolones, and susceptibility to aminoglycosides and carbapenems. Patients with solid cancer and ESBL-E infections require special management since they are a population with a high threat of antibiotic-resistant infections. Carbapenems and aminoglycosides remain active antibiotics against these infections.\n <\/jats:p>","DOI":"10.1089\/mdr.2020.0530","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T13:59:11Z","timestamp":1626357551000},"page":"1470-1481","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical and Molecular Findings of Infections Caused by Extended-Spectrum \u03b2-Lactamase-Producing\n Enterobacterales<\/i>\n in Patients with Solid Tumors: A Single-Center Study"],"prefix":"10.1177","volume":"27","author":[{"given":"Maria","family":"Szymankiewicz","sequence":"first","affiliation":[{"name":"Department of Microbiology, prof. F. \u0141ukaszczyk Centre of Oncology in Bydgoszcz, Bydgoszcz, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Stefaniuk","sequence":"additional","affiliation":[{"name":"Department of Antibiotics and Microbiology, National Medicines Institute, Warsaw, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Baraniak","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology, National Medicines Institute, Warsaw, Poland."},{"name":"Department of Drug Biotechnology and Bioinformatics, National Medicines Institute, Warsaw, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Nowikiewicz","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Nicolaus Copernicus University Ludwik Rydygier's Collegium Medicum, Bydgoszcz, Poland."},{"name":"Clinical Department of Breast Cancer and Reconstructive Surgery, prof. F. \u0141ukaszczyk Centre of Oncology in Bydgoszcz, Bydgoszcz, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0146-1"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28027"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-016-3635-6"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.05.034"},{"key":"e_1_3_3_6_2","author":"Puig-Asensio M.","unstructured":"Puig-Asensio M., I. Ruiz-Camps, M. Fern\u00e1ndez-Ruiz, et al. 2015. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. Clin. Microbiol. Infect. 21:491.e1\u2013491.e10.","journal-title":"et al"},{"key":"e_1_3_3_7_2","first-page":"59","article-title":"Bloodstream infections in cancer patients","volume":"71","author":"Islas-Mu\u00f1oz B.","year":"2018","unstructured":"Islas-Mu\u00f1oz B., , Volkow-Fern\u00e1ndez P., , Ibanes-Guti\u00e9rrez C., , Villamar-Ram\u00edrez A., , Vilar-Compte D., , and Cornejo-Ju\u00e1rez P.. 2018. Bloodstream infections in cancer patients. Risk factors associated with mortality. Int. J. Infect. Dis. 71:59\u201364.","journal-title":"Risk factors associated with mortality. Int. J. Infect. Dis"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e31823bd6db"},{"key":"e_1_3_3_9_2","first-page":"Cham","article-title":"Bacterial and atypical infections in critically ill cancer patients","author":"De la Hoz A.","year":"2020","unstructured":"De la Hoz A., , and Cort\u00e9s J.A.. 2020. Bacterial and atypical infections in critically ill cancer patients. In J. Nates and K. Price (eds.), Oncologic critical care. Springer, Cham. DOI: 10.1007\/978-3-319-74588-6_123. pp.1379\u20131400.","journal-title":"In J. Nates and K. Price (eds.), Oncologic critical care"},{"key":"e_1_3_3_10_2","author":"Hendrik T.C.","year":"2015","unstructured":"Hendrik T.C., , Voor In \u2018t Holt A.F, , and Vos M.C.. 2015. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella spp.: a systematic review and meta-analyses. PLoS One 10:e0140754.","journal-title":"Klebsiella"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21462"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2019.24.41.1800594"},{"key":"e_1_3_3_13_2","unstructured":"National Antibiotic Protection Program. 2016. Definitions for healthcare associated infections (HAI) effective January 1 2016. [Definicje zaka\u017ce\u0144 zwi\u0105zanych z opiek\u0105 zdrowotn\u0105 (HAI) obowi\u0105zuj\u0105ce od 1 stycznia 2016 r.\/\/]. Available at https:\/\/www.antybiotyki.edu.pl (accessed February25 2021)."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/45.4_ts.493"},{"key":"e_1_3_3_15_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoints tables for interpretation of MICs and zone diameters. v 9.0. Available at https:\/\/www.eucast.org (accessed February25 2021)."},{"key":"e_1_3_3_16_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2017. EUCAST guideline for the detection of resistance mechanisms and specific resistance of clinical and\/or epidemiological importance. v 2.0. Available at https:\/\/www.eucast.org\/resistance_mechanisms (accessed February25 2021)."},{"key":"e_1_3_3_17_2","unstructured":"\u017babicka D. Baraniak A. Literacka E. Gniadkowski M. and Hryniewicz W.. 2017. Detection of carbapenemases production\u2014recommendations [in Polish]. NIL Warszawa Poland."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00284-020-02334-3"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90331-I"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.9.2233-2239.1995"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.66.10.4555-4558.2000"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.5603\/GP.a2018.0106"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2019.01.020"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2009.02.002"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.07.018"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.12.003"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2012.01.040"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2020.52.1.59"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1592-1"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.11.025"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.07.010"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00125-13"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.6498"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.011"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.04.022"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz571"},{"key":"e_1_3_3_37_2","unstructured":"EARS-Net European Centre for Disease Prevention and Control. 2019. Surveillance of Antimicrobial Resistance in Europe \u2013 Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2018. ECDC Stockholm."},{"key":"e_1_3_3_38_2","first-page":"187","article-title":"ESBL-producing Escherichia coli isolated from children with acute diarrhea\u2014antimicrobial susceptibility, adherence patterns and phylogenetic background","volume":"21","author":"Franiczek R.","year":"2012","unstructured":"Franiczek R., , Sobieszcza\u0144ska B., , Turniak M., et al. 2012. ESBL-producing Escherichia coli isolated from children with acute diarrhea\u2014antimicrobial susceptibility, adherence patterns and phylogenetic background. Adv. Clin. Exp. Med. 21:187\u2013192.","journal-title":"Adv. Clin. Exp. Med"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky296"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2015.11.028"},{"key":"e_1_3_3_41_2","volume-title":"et al","author":"Sepp E.","unstructured":"Sepp E., , Andreson R., , Balode A., et al. 2019. Phenotypic and molecular epidemiology of ESBL-, AmpC-, and carbapenemase-producin, g Escherichia coli, in Northern and Eastern Europe. Front. Microbiol. 10: , 2465."},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-0237-2"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S192072"},{"key":"e_1_3_3_44_2","first-page":"108","article-title":"Multiple drug resistance patterns in various phylogenetic groups of hospital-acquired uropathogenic E","volume":"9","author":"Mahmoud A.T.","year":"2020","unstructured":"Mahmoud A.T., , Salim M.T, , Ibrahem R.A, , Gabr A., , and Halby H.M.. 2020. Multiple drug resistance patterns in various phylogenetic groups of hospital-acquired uropathogenic E. coli isolated from cancer patients. Antibiotics (Basel), 9:108.","journal-title":"coli isolated from cancer patients. Antibiotics (Basel)"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i21.6560"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2020.0530","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2020.0530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:39:04Z","timestamp":1777667944000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2020.0530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11,1]]}},"alternative-id":["10.1089\/mdr.2020.0530"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2020.0530","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}